1 active not recruiting, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Myeloma, Multiple: new trials by email Literature Review of Myeloma, Multiple trials Research Report on Myeloma, Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM Lenalidomide, Ixazomib, Daratumumab Injection - Myeloma, Multiple | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 79 | 2020-10-21 | 2025-12-18 |
| Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma Avelumab, External beam radiotherapy - Myeloma, Multiple, Myeloma-Multiple | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2019-10-17 | 2021-05-12 |
Multiple Myeloma (2)
Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2) · Vascular Diseases (2)
Calcium Dobesilate (1) · Dexamethasone (1) · Lenalidomide (1) · avelumab (1) · daratumumab (1) · ixazomib (1)
Alliance Foundation Trials, LLC. (1) · National Cancer Institute (NCI) (1)
United States (2)
Andrew Yee, MD (1) · Evanthia Galanis, MD (1) · Mark Roschewski, M.D. (1)